Combination aerosol therapy to treat Burkholderia cepacia complex

Middleton, P. G., Kidd, T. J. and Williams, B. (2005) Combination aerosol therapy to treat Burkholderia cepacia complex. The European Respiratory Journal, 26 2: 305-308. doi:10.1183/09031936.05.00119504


Author Middleton, P. G.
Kidd, T. J.
Williams, B.
Title Combination aerosol therapy to treat Burkholderia cepacia complex
Journal name The European Respiratory Journal   Check publisher's open access policy
ISSN 0903-1936
1399-3003
Publication date 2005-05-03
Year available 2005
Sub-type Article (original research)
DOI 10.1183/09031936.05.00119504
Volume 26
Issue 2
Start page 305
End page 308
Total pages 6
Place of publication Lausanne, Switzerland
Publisher European Respiratory Society
Language eng
Subject 111502 Clinical Pharmacology and Therapeutics
Formatted abstract
Burkholderia cepacia infection in cystic fibrosis (CF) patients is associated with significant morbidity and mortality, yet no definitive treatment is currently available. This report describes a new approach to treat B. cepacia infection in CF patients, using a combination of amiloride and tobramycin aerosols.

Four adults with the typical clinical syndrome of CF were recruited after repeated positive sputum cultures for B. cepacia. Aerosols of amiloride and tobramycin were given three times daily for 1–6 months, and repeated sputum cultures were collected to assess efficacy.

Three of the four patients treated with the combined therapy eradicated B. cepacia from their sputum cultures for at least 2 yrs, and there were no adverse events.

This novel combination may provide a new therapeutic option for Burkholderia cepacia infections. Furthermore, the strategy of combining antibiotics with ion transport agents may have ramifications for the treatment of other multi-resistant organisms.
Keyword Aerosol
amiloride
Burkholderia cepacia complex
cystic fibrosis
tobramycin
References # Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984;104:206–210.[ISI][Medline] [Order article via Infotrieve] # Cohn RC, Jacobs M, Aronoff SC. In vitro activity of amiloride combined with tobramycin against Pseudomonas isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 1988;32:395–396.[Abstract/Free Full Text] # Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990;322:1189–1194.[Abstract] # Graham A, Hasani A, Alton EWFW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993;6:1243–1248.[Abstract] # Touw DJ, Brimicombe RW, Hodson ME, Heijerman HG, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995;8:1594–1604.[Abstract] # Segonds C, Heulin T, Marty N, Chabanon G. Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. J Clin Microbiol 1999;37:2201–2208.[Abstract/Free Full Text] # Mahenthiralingam E, Bischof J, Byrne SK, et al. DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol 2000;38:3165–3173.[Abstract/Free Full Text] # Henry DA, Mahenthiralingam E, Vandamme P, Coenye T, Speert DP. Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex. J Clin Microbiol 2001;39:1073–1078.[Abstract/Free Full Text] # Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001;33:1469–1475.[CrossRef][ISI][Medline] [Order article via Infotrieve] # Jones AM, Dodd ME, Govan JRW, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004;59:948–951.[Abstract/Free Full Text] # Lipuma JJ, Marks-Austin KA, Holsclaw DS, Jr, Winnie GB, Gilligan PH, Stull TL. Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis. Pediatr Infect Dis J 1994;13:716–719.[ISI][Medline] [Order article via Infotrieve] # Cohn RC, Rudzienski L, Putnam RW. In vitro antimicrobial activity of amiloride analogs against Pseudomonas. Chemotherapy 1992;38:232–237.[ISI][Medline] [Order article via Infotrieve] # Cohn RC, Rudzienski L. Substituted amines synergistic with tobramycin against Burkholderia cepacia in vitro. Chemotherapy 1997;43:100–107.[ISI][Medline] [Order article via Infotrieve] # Cohn RC, Aronoff SC. The effect of sodium on amiloride-tobramycin synergy in Pseudomonas cepacia. J Lab Clin Med 1989;114:724–727.[ISI][Medline] [Order article via Infotrieve] # Gaston B, Ratjen F, Vaughan JW, et al. Nitrogen redox balance in the cystic fibrosis airway: effects of antipseudomonal therapy. Am J Respir Crit Care Med 2002;165:387–390.[Abstract/Free Full Text] # Middleton PG, Geddes DM, Alton EWFW. Trimethoprim and tetracycline inhibit airway epithelial sodium absorption. Am J Respir Crit Care Med 1996;154:18–23.[Abstract]
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 21 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 20 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Fri, 09 Jan 2009, 16:20:11 EST by Judy Dingwall on behalf of School of Medicine